Dr. Reddy's Laboratories allowed to produce generic semaglutide, setting potential precedent for others.
ByAinvest
Wednesday, Dec 3, 2025 10:22 am ET1min read
RDY--
The Delhi High Court has ruled in favor of Dr Reddy's Laboratories, allowing it to manufacture and export its generic version of semaglutide in non-protected markets. This ruling may set a precedent for other similar cases, according to legal experts. However, sales of the generic version in India are blocked until the patent expires in March 2026.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet